Dr Lal PathLabs Q1: consolidated PAT up 27% YoY to ₹170.5 Cr, EBITDA margin beats guidance
PAT +27.2% YoY · revenue +19.1% · margins expanding · beat vs street
₹797.7 Cr
+19.1% YoY
₹170.5 Cr
+27.2% YoY
20.55%
+1.4pp YoY
₹10.15
Dr Lal PathLabs opened FY27 with a broad-based beat. Consolidated revenue from operations rose 19.1% YoY to ₹797.7 Cr and net profit climbed 27.2% to ₹170.5 Cr (₹134.0 Cr a year ago), with basic EPS at ₹10.15 (post the 1:1 bonus, vs a restated ₹7.94). Sequentially the print is also strong — revenue +13.5% and PAT +29% QoQ off the ₹702.7 Cr / ₹132.2 Cr March quarter — and diagnostics is not a seasonal business, so the QoQ step-up is genuine momentum rather than a calendar artifact. There were no exceptional items in either comparison quarter, so the reported growth is the underlying growth.
Q1 FY-2027 vs prior quarters
The standout is margin. EBITDA margin expanded to ~31% from 28.7% a year earlier and net margin to 21.4% from 19.2%, even as depreciation jumped 28% YoY to ₹44.4 Cr and finance costs rose on an enlarged base — the operating leverage came through on materials and collection-centre costs holding their revenue share. Part of the topline is inorganic: Shahbazkers Diagnostic Centre was consolidated from May 1, 2026, and the group also incorporated a Dubai subsidiary (FZCO) during the quarter, so some of the 19% is acquired volume rather than pure organic testing growth.
The stock went into the print at ₹1,697.6, up 2.2% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
What the summary numbers don't show
No exceptional item this quarter — the ₹30.1 Cr Labour Codes charge sat in FY26 full-year, so YoY growth needs no adjustment.
Management projects an acceleration in revenue growth to an 'early to mid-teens' range for FY27, driven by sustained network expansion and strong performance in core markets. They expect to maintain healthy EBITDA margins between 27% and 28%, choosing to reinvest any potential upside back into the business for future g
— This quarter: beat
Against management's own FY27 guidance — 'early-to-mid-teens' revenue growth and a 27–28% EBITDA margin band, with upside to be reinvested — the quarter runs ahead on both counts: revenue at +19% and margin at ~31% sit above the guided ranges, an early beat vs the confident-but-conservative framing from the Q4 concall. It also runs ahead of street, where consensus (Trendlyne, 26 analysts) models ~13% revenue and ~17% profit growth for the full year. Alongside the result the board declared a ₹5/share interim dividend, granted 119,300 stock options, and approved two bolt-ons announced the same day — an 80% stake in Ghana's Sunshine Healthcare (up to ₹38 Cr) and 30% of Neuome Technologies (up to ₹3.5 Cr) — extending the acquisitive posture into West Africa and pre-analytics. The recent income-tax appeal win on ESOP expenses is a positive but did not drive this quarter's tax line, where the effective rate normalised to ~25.4%.
W1
Revenue durability vs the 'early-to-mid-teens' FY27 guide: Q1 printed +19% YoY, but part is Shahbazkers/inorganic — watch organic volume growth as the base laps.
W2
EBITDA margin sustainability: Q1 at ~31% is above the guided 27–28%; management said upside would be reinvested, so monitor whether margin normalises down.
W3
Capex/expansion execution: ₹100–120 Cr guided for 12–15 new labs plus integration of Ghana (SHL) and Neuome — track lab additions and margin drag next quarter.
Source in INR million, converted to ₹ Cr (÷10). No exceptional item this quarter; ₹30.1 Cr Labour Codes charge was booked in FY26 full-year only, so YoY comps are clean. Consolidated PAT ₹170.5 Cr is total (owners ₹169.5 Cr + NCI ₹1.0 Cr); matches DB convention (prior-qtr netProfit used total). Year-ago EPS in our context (₹15.88) is pre-bonus; filing restates it to ₹7.94 post 1:1 bonus (Dec-2025).
Informational and educational content only. Not investment advice.